Having trouble accessing articles? Reset your cache.

Galapagos maintains independence, adds R&D firepower with $5.1 billion megadeal with Gilead

A partnership with Gilead allows Galapagos to nearly double the size of its clinical pipeline, with the potential to add new technology platforms via BD, and ensures its independence into the next decade.

Under the July 14 R&D collaboration, Gilead Sciences Inc. (NASDAQ:GILD) will pay Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) $3.95 billion in cash up front, plus make a $1.1 billion equity investment to get an option to nearly all of Galapagos' clinical pipeline over the next 10 years. Galapagos has six clinical programs -- most of which are first in class -- and more than 20 preclinical programs.

According to BioCentury's BCIQ

Read the full 1002 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers